Vir Biotechnology Inc. (VIR)
NASDAQ: VIRHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD
At close: Oct 7, 4:00 PM ET · Delayed 15 min
VIR stock chart
Technical analysisKey statistics
All statistics- Market cap
- $1.95B
- EPS (TTM)
- -$1.74
- Dividend yield
- None
- 52-week range
- 4.82 – 11.94
- Day range
- 11.32 – 11.77
- Volume / Avg
- 3.56M / 1.87M
- Beta
- —
- Shares outstanding
- 169.22M
- Next earnings
- Nov 4, 2026
52-week range
VIR stock today
On Oct 7, VIR ended the session at $11.52, shedding $0.08 (0.69%), versus the S&P 500's 0.22% decline. Shares are 3.5% below their 52-week high of $11.94, set on Sep 2, 2026 and 139.3% above the 52-week low of $4.82, near the top of the past year's range. VIR is up 91.0% year to date, outperforming the S&P 500 (+14.0%). Over the past 12 months, the stock has gained 103.5%.
Vir Biotechnology has posted a net loss over the last twelve months (EPS of -$1.74), so its P/E ratio is not meaningful. Vir Biotechnology's next earnings report is expected on Nov 4, 2026.
Summary generated from market data by MetaCap's automated system. Methodology
About Vir Biotechnology
Company profileVir Biotechnology, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapeutic products to treat and prevent serious infectious diseases in the United States and internationally. Its clinical development pipeline consists of product investigational therapies targeting hepatitis delta virus (HDV) and other solid tumors. The company's preclinical candidates include those targeting influenza A and B antibodies and antibody drug conjugates, and coronavirus monoclonal antibodies; and PRO-XTEN, a dual-masked TCEs targeting variety of solid tumors.
- Sector
- Health Care
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- CEO
- Dr. Marianne De Backer M.B.A., M.Sc., Ph.D.
- Headquarters
- San Francisco, CA
- Employees
- 367
- IPO year
- 2019
- Website
- vir.bio
Analyst forecast
ForecastConsensus (10 analysts)
strong_buy
Avg. price target
$20.78+80.38%
- Strong buy 3
- Buy 7
- Hold 0
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Earnings
Earnings history- Next report
- Nov 4, 2026
- EPS estimate
- $-0.80
Vir Biotechnology peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| VCELVericel Corporation | 40.74 | +1.72% | $2.09B | vs VIR |
| ALVOAlvotech | 5.85 | -4.72% | $2.09B | vs VIR |
| MESOMesoblast Limited ADR | 13.94 | +2.42% | $1.81B | vs VIR |
| BCRXBioCryst Pharmaceuticals Inc. | 8.40 | +5.66% | $2.15B | vs VIR |
| ADMAADMA Biologics Inc | 10.14 | -0.39% | $2.27B | vs VIR |
| RXRXRecursion Pharmaceuticals Inc. Class A | 4.27 | -7.78% | $2.29B | vs VIR |
| BEAMBeam Therapeutics Inc. | 24.77 | -1.82% | $2.56B | vs VIR |
| TARSTarsus Pharmaceuticals Inc. | 73.61 | -0.67% | $3.44B | vs VIR |
Indexes, lists and sector
Vir Biotechnology stock FAQ
What is Vir Biotechnology's stock price today?
VIR last traded at $11.52 as of Oct 7, 4:00 PM EDT, down 0.69% on the day. Prices are delayed at least 15 minutes.
When is Vir Biotechnology's next earnings date?
Vir Biotechnology is expected to report earnings on Wednesday, November 4, 2026. Analysts expect EPS of $-0.80.
Who is Vir Biotechnology's CEO?
Dr. Marianne De Backer M.B.A., M.Sc., Ph.D. is the chief executive officer of Vir Biotechnology Inc., which has about 367 employees.
What is the VIR 52-week high?
The 52-week high for VIR is $11.94 and the 52-week low is $4.82. The stock is currently 3.5% below its high.